Antibody Humanization Service
Antibody humanization is a critical step in the development of therapeutic and translational antibodies derived from non-human species. The process typically involves modifying rodent or other non-human antibody sequences to reduce immunogenicity while preserving antigen-binding specificity and functional activity. Humanized antibodies are widely used in therapeutic discovery, preclinical evaluation, and advanced biologics research due to their improved compatibility with the human immune system.
At Biocrest Science, we provide flexible antibody humanization services designed to support researchers working with monoclonal antibodies, recombinant antibodies, and lead therapeutic candidates. Our workflows combine sequence engineering, structural analysis, and recombinant expression strategies to help optimize antibody developability while maintaining target-binding performance.
Humanization Strategies
Different antibodies require different engineering approaches depending on sequence characteristics, framework compatibility, and downstream application requirements.
| Strategy | Best For | Key Features |
|---|---|---|
| CDR Grafting | Standard murine monoclonal antibodies | Transfers complementarity-determining regions (CDRs) into human frameworks |
| Framework Engineering | Affinity-sensitive antibodies | Selective back-mutation to preserve binding activity |
| Human Framework Selection | Early-stage therapeutic optimization | Identification of compatible germline frameworks |
| Affinity Recovery Optimization | Antibodies with reduced activity after grafting | Sequence refinement to restore binding performance |
Humanization strategies are selected based on antibody sequence analysis, structural considerations, and intended downstream use.
Supported Antibody Formats
We support humanization projects for multiple antibody formats, including:
- Full-length IgG antibodies
- Mouse monoclonal antibodies
- Rabbit-derived antibodies
- Recombinant antibody sequences
- Fab and scFv fragments
- Bispecific or engineered antibody formats (upon request)
If only hybridoma cells or partial sequence data are available, upstream sequencing services can also be incorporated into the workflow.
Applications & Use Cases
Humanized antibodies generated through our services are commonly used in:
- Therapeutic antibody discovery
- Preclinical research
- Functional antibody characterization
- Assay development and translational studies
- Recombinant antibody engineering workflows
Application-specific validation is not automatically included for all projects. Validation and characterization plans are determined based on project goals and can be customized upon request.
Overview of the Workflow
| Phase | Service | Description | Deliverables | Timeline |
|---|---|---|---|---|
| Phase 1 | Sequence Analysis | Evaluation of antibody variable regions and framework compatibility | Sequence assessment report | ~1 week |
| Phase 2 | Humanization Design | CDR grafting and framework engineering | Humanized antibody sequence design | 1–2 weeks |
| Phase 3 | Recombinant Expression | Expression of humanized antibody in mammalian systems | Purified recombinant antibody | 2–3 weeks |
| Phase 4 | Quality Control & Validation | Basic QC and optional binding validation | QC report, expression data | 1 week |
Typical total timeline: ~4–7 weeks
Timelines may vary depending on sequence complexity, optimization requirements, and validation scope.
Expression & Optimization Options
Depending on project requirements, additional optimization services may include:
- Codon optimization
- Isotype switching
- Fc engineering
- Affinity recovery optimization
- Stability assessment
- Transient HEK293 or CHO expression
Expression system selection is based on antibody format and intended downstream application.
Quality & Validation
We implement quality control and characterization strategies appropriate for recombinant antibody engineering workflows.
Standard Quality Control
Sequence verification, Purity assessment (SDS-PAGE), Concentration determination
Functional Validation (performed upon request)
Binding validation (e.g., ELISA), Comparative binding analysis against parental antibody, Application-specific testing
Optional Characterization
Affinity measurement (SPR or BLI), Developability assessment, Aggregation analysis (SEC-HPLC)
Validation scope is defined during project planning and adjusted based on research objectives.
Why Researchers Choose Biocrest Science
- Flexible humanization strategies – Tailored engineering approaches based on antibody sequence and application
- Integrated recombinant expression capability – Sequence-to-expression workflow within a single project pipeline
- Balanced optimization approach – Focus on reducing immunogenicity while maintaining binding performance
- Transparent project communication – Clear timelines, deliverables, and optimization checkpoints
- Support for therapeutic research workflows – Compatible with early-stage discovery and preclinical development projects
Because antibody behavior can change during framework engineering, optimization requirements may vary between projects. Our team works to evaluate potential risks early and develop practical engineering strategies accordingly.
Start Your Project
Whether you are advancing a therapeutic candidate or optimizing an antibody for translational research, our team can help design a humanization workflow aligned with your project goals.
- Submit antibody sequences or hybridoma information for evaluation
- Consult with our scientists on humanization strategy selection
- Request a quote based on antibody format and downstream requirements
📩 Typical response time: 1–2 business days
Contact us to discuss your antibody humanization project.
Contact Biocrest Science →